Mode
Text Size
Log in / Sign up
N/A N=62

DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial

Femoral Fracture (Proximal)

Enrolled (actual)
62
Serious AEs
4.8%
Results posted
Dec 2010
Primary outcome: Primary: Success in Terms of the Merle D'Aubigne Postel Score for Pain Category — 4.1; 4.4; 4.5; 4.6 Units on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Intramedullary nailing (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
DePuy Orthopaedics
Primary completion
Sep 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Success in Terms of the Merle D'Aubigne Postel Score for Pain Category
4.1; 4.4; 4.5; 4.6
PRIMARY
Success in Terms of the Merle D'Aubigne Postel Score for Walk Category
1.3; 2.6; 3.0; 2.7
PRIMARY
Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category
5.2; 5.4; 5.4; 5.6
SECONDARY
Lower Extremity Measure (LEM)
SECONDARY
Medical Imaging
SECONDARY
Six Item Screener and Ambulatory Status
SECONDARY
SF-12

Summary

The purpose of this study is to monitor trochanteric fracture healing and review the performance of the ATN system.

Eligibility Criteria

Inclusion Criteria

  • Ability to understand and willing to sign the approved consent form.
  • 18 years of age
  • Skeletally mature
  • Have stable or unstable proximal femur fracture, including pertrochanteric, intertrochanteric, high subtrochanteric or any combination of the AO Proximal Femur Fracture Classification

Exclusion Criteria

  • Subjects with concomitant lower extremity injuries or multiple trauma that would interfere with normal hip fracture rehabilitation.
  • Subjects who have isolated or combined medial femoral neck fractures.
  • Subjects who are unwilling or unable to comply with a rehabilitation program or are unwilling or unable to be assessed for 1 year following surgery.
  • Subjects who are pregnant or breastfeeding.
  • Subjects who are a prisoner or a known alcohol or drug abuser.
  • Subjects who have a prior surgical history in the affected hip, or conditions that may interfere with outcome or impede healing.
  • Subjects who have an obliterated medullary canal or other conditions that may complicate the reaming process.
  • Subjects who have evidence of active untreated infections that may spread to other areas of the body.
  • Subjects who have a highly communicable disease or pathology that may limit follow-up.
  • Subjects, who in the opinion of the Clinical Investigator, have an existing condition that indicates the Subject is not a good candidate for the study.
  • Subjects who are participating in another clinical investigation.
  • Subjects known to have allergies to titanium, aluminum, vanadium.
  • Subjects who are currently eligible for workman's compensation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00546429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search